Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Herceptin Adjuvant Approval Has 65% Higher Price Than Metastatic Therapy

Executive Summary

The average cost per one-year course of Herceptin (trastuzumab) for adjuvant HER2-positive breast cancer will be $38,007, or 65% more than a course for the biologic's metastatic breast cancer indication

You may also be interested in...



Avastin Growth Cut By Colorectal Cancer Competition, Genentech Says

Avastin (bevacizumab) utilization in second-line metastatic colorectal cancer is taking a hit from competitor products, Genentech reported during its April 11 first-quarter earnings call

Avastin Growth Cut By Colorectal Cancer Competition, Genentech Says

Avastin (bevacizumab) utilization in second-line metastatic colorectal cancer is taking a hit from competitor products, Genentech reported during its April 11 first-quarter earnings call

GSK Tykerb Priced At Discount To Herceptin In Metastatic Breast Cancer

GlaxoSmithKline is pricing its breast cancer therapy Tykerb at a slight discount to Genentech's Herceptin (trastuzumab) in the metastatic breast cancer setting

Related Content

UsernamePublicRestriction

Register

OM007016

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel